Takeda Pharmaceutical Company Limited (TKPHF)
TKPHF Stock Price Chart
Explore Takeda Pharmaceutical Company Limited interactive price chart. Choose custom timeframes to analyze TKPHF price movements and trends.
TKPHF Company Profile
Discover essential business fundamentals and corporate details for Takeda Pharmaceutical Company Limited (TKPHF) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
25 Jun 2008
Employees
49.28K
Website
https://www.takeda.comCEO
Christophe Weber
Description
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.
TKPHF Financial Timeline
Browse a chronological timeline of Takeda Pharmaceutical Company Limited corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 May 2026
Upcoming earnings on 28 Jan 2026
Upcoming earnings on 30 Oct 2025
Revenue estimate is $8.08B.
Earnings released on 30 Jul 2025
EPS came in at $0.54 surpassing the estimated $0.34 by +57.02%, while revenue for the quarter reached $7.64B , missing expectations by -3.91%.
Earnings released on 25 Jun 2025
EPS came in at -$0.45 , while revenue for the quarter reached $7.24B .
Dividend declared on 8 May 2025
A dividend of $0.69 per share was announced, adjusted to $0.69.
Dividend declared on 8 May 2025
A dividend of $0.69 per share was announced, adjusted to $0.69. The dividend will be paid on 1 Dec 2025.
Earnings released on 30 Jan 2025
EPS came in at $0.10 surpassing the estimated $0.00 by +14.66K%, while revenue for the quarter reached $7.28B , beating expectations by +0.55%.
Earnings released on 31 Oct 2024
EPS came in at $0.38 surpassing the estimated $0.10 by +266.79%, while revenue for the quarter reached $7.91B , beating expectations by +4.38%.
Earnings released on 31 Jul 2024
EPS came in at $0.41 surpassing the estimated $0.00 by +33.18K%, while revenue for the quarter reached $7.52B , beating expectations by +10.81%.
Earnings released on 9 May 2024
EPS came in at -$0.01 falling short of the estimated $0.01 by -276.16%, while revenue for the quarter reached $6.93B , beating expectations by +15.76%.
Dividend declared on 9 May 2024
A dividend of $0.65 per share was announced, adjusted to $0.65. The dividend was paid on 26 Jun 2025.
Dividend declared on 9 May 2024
A dividend of $0.68 per share was announced, adjusted to $0.68. The dividend was paid on 2 Dec 2024.
Earnings released on 1 Feb 2024
EPS came in at $0.46 surpassing the estimated $0.20 by +124.27%, while revenue for the quarter reached $7.94B , beating expectations by +11.61%.
Earnings released on 26 Oct 2023
EPS came in at -$0.21 falling short of the estimated $0.32 by -165.63%, while revenue for the quarter reached $6.98B , beating expectations by +4.99%.
Earnings released on 27 Jul 2023
EPS came in at $0.41 falling short of the estimated $0.60 by -31.69%, while revenue for the quarter reached $7.33B , beating expectations by +6.86%.
Earnings released on 11 May 2023
EPS came in at $0.14 surpassing the estimated $0.10 by +40.44%, while revenue for the quarter reached $7.22B , beating expectations by +0.19%.
Dividend declared on 11 May 2023
A dividend of $0.62 per share was announced, adjusted to $0.62. The dividend was paid on 27 Jun 2024.
Dividend declared on 11 May 2023
A dividend of $0.63 per share was announced, adjusted to $0.63. The dividend was paid on 1 Dec 2023.
Earnings released on 2 Feb 2023
EPS came in at $0.59 surpassing the estimated $0.57 by +3.70%, while revenue for the quarter reached $8.45B , beating expectations by +10.65%.
Earnings released on 27 Oct 2022
EPS came in at $0.27 surpassing the estimated $0.26 by +2.16%, while revenue for the quarter reached $6.93B , beating expectations by +5.61%.
Earnings released on 28 Jul 2022
EPS came in at $0.50 falling short of the estimated $0.60 by -15.63%, while revenue for the quarter reached $7.15B , beating expectations by +3.63%.
Earnings released on 11 May 2022
EPS came in at -$0.06 falling short of the estimated $0.13 by -144.23%, while revenue for the quarter reached $7.14B , beating expectations by +3.18%.
Dividend declared on 11 May 2022
A dividend of $0.68 per share was announced, adjusted to $0.68. The dividend was paid on 29 Jun 2023.
Dividend declared on 11 May 2022
A dividend of $0.62 per share was announced, adjusted to $0.62. The dividend was paid on 1 Dec 2022.
Earnings released on 3 Feb 2022
EPS came in at $0.32 falling short of the estimated $0.70 by -53.86%, while revenue for the quarter reached $7.84B , beating expectations by +7.96%.
Earnings released on 28 Oct 2021
EPS came in at $0.26 , while revenue for the quarter reached $7.58B , beating expectations by +2.49%.
Earnings released on 30 Jul 2021
EPS came in at $1.16 surpassing the estimated $0.81 by +44.10%, while revenue for the quarter reached $8.54B .
Earnings released on 11 May 2021
EPS came in at $1.15 , while revenue for the quarter reached $6.97B .
Dividend declared on 11 May 2021
A dividend of $0.74 per share was announced, adjusted to $0.73. The dividend was paid on 30 Jun 2022.
Dividend declared on 11 May 2021
A dividend of $0.80 per share was announced, adjusted to $0.81. The dividend was paid on 1 Dec 2021.
Earnings released on 4 Feb 2021
EPS came in at $0.56 , while revenue for the quarter reached $8.10B .
Earnings released on 29 Oct 2020
EPS came in at $0.02 , while revenue for the quarter reached $7.47B .
Dividend declared on 13 May 2020
A dividend of $0.82 per share was announced, adjusted to $0.82. The dividend was paid on 30 Jun 2021.
Dividend declared on 13 May 2020
A dividend of $0.85 per share was announced, adjusted to $0.85. The dividend was paid on 1 Dec 2020.
TKPHF Stock Performance
Access detailed TKPHF performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.